8-KEarnings & ResultsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Jul 19, 2022)

Filed July 19, 2022For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on July 18, 2022, to report its second-quarter financial results for the period ended July 3, 2022. The filing includes a press release detailing the company's sales and earnings performance for the quarter. Investors can find specific sales figures and earnings per share within the accompanying press release and supplementary sales data, which are attached as exhibits to this report. These documents provide insight into the company's operational performance and financial condition during the second quarter of 2022. While the 8-K itself is a notification of the release of these results, the attached exhibits are crucial for understanding the actual financial figures. Investors should refer to the press release (Exhibit 99.1) and the unaudited comparative supplementary sales data and condensed consolidated statement of earnings (Exhibit 99.2) for a comprehensive overview of JNJ's Q2 2022 performance, including key metrics such as revenue, net earnings, and earnings per share, broken down by segment and geographic region if provided.

Key Highlights

  • 1Johnson & Johnson announced its second-quarter 2022 financial results on July 19, 2022, via an 8-K filing.
  • 2The filing provides sales and earnings information for the quarter ended July 3, 2022.
  • 3Key financial details are available in the attached press release (Exhibit 99.1).
  • 4Unaudited comparative supplementary sales data and condensed consolidated statements of earnings are included as Exhibit 99.2.
  • 5Investors can analyze the company's revenue and profit performance for the specified period.
  • 6The report serves as an official notification of the release of JNJ's Q2 2022 financial performance.
  • 7The Inline XBRL formatted cover page is included as Exhibit 104 for data accessibility.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and report Johnson & Johnson's sales and earnings results for the second quarter ended July 3, 2022. It serves as a public notification mechanism for these significant financial updates.

The detailed financial results, including sales and earnings, can be found in the exhibits attached to this 8-K filing. Specifically, investors should refer to Exhibit 99.1 (Press Release dated July 19, 2022) and Exhibit 99.2 (Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings).

This specific 8-K filing primarily reports on the past financial performance for the second quarter of 2022. While the attached press release might contain commentary on future outlook or guidance, the 8-K itself is focused on reporting historical results. Investors should carefully review the content of Exhibit 99.1 for any forward-looking statements or guidance provided by the company.

Investors should look for key financial metrics such as total sales and revenue, net earnings, earnings per share (EPS), and potentially segment-specific sales performance (e.g., Pharmaceuticals, MedTech, Consumer Health) and geographic sales breakdowns, as detailed in the press release and supplementary financial data.